Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial)

American Journal of Cardiology

Volumn 81, Issue 5, 1998, Pages 632-636

  Boccuzzi, Stephen J ^b   Weintraub, William S ^a   Kosinski, Andrzej S ^b   Roehm, James B ^b   Klein, J Larry ^b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MEVINOLIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TREATMENT OUTCOME;

EID: 0032031806     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00980-6     Document Type: Article

References (20)

1. Gellman J, Ezekowitz M, Sarembock IJ, Azxrim MA, Nochomowitz LE, Lerner E, Haudenschild CC. Effects of lovastatin on intimal hyperplasia after balloon angioplasty: a study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol 1991;17:251-259.
2. Sahni R, Maniet AR, Voci G, Banka VS. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991;121:1600-1608.
3. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB III, Ivanhoe R, Cedarholm JC, Stillabower ME, Talley MD, DeMaio SJ, O'Neill WW, Frazier JE II, Cohen-Bernstein CL, Robbins DC, Brown CL III, Alexander RW, and the Lovastatin Restenosis Trial Study Group. Lack of effect on restenosis after coronary angioplasty. N Engl J Med 1994;331:1331-1337.
4. Weintraub WS, Boccuzzi SJ, Brown CL III, Cohen CL, Hirsch LJ, King SB III, Alexander RW, and the Lovastatin Restenosis Trial Study Group. Background and methods for the Lovastatin Restenosis Trial after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;70:293-299.
5. Klein JL, Treasure CB, Manoukian SV, Vogel RA, Beauman GJ, Fischman D, Savage MP, Boccuzzi SJ, Weintraub WS, for the Lovastatin Restenosis Trial Group. Performance standards and edge detection with computerized quantitative coronary arteriography. Am J Cardiol 1996;77:815-822.
6. Schwartz SM, deBlois D, O'Brien RM. The intima: soil for artherosclerosis and restenosis. Circ Res 1995;77:445-465.
7. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992; 86(suppl III):III-47-III-52.
8. Weintraub WS, Pederson TR. Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study. Am J Cardiol 1996;78:1036-1038.
9. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan CK, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
10. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-638.
11. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J. Effect of monotherapy with an HMG CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-968.
12. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park JS, McGovern ME, for the PLAC I Investigators. Pravastatin limitation of atherosclerosis in the coronary arteries. (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995;26:1133-1139.
13. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi, SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
14. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effects of cholesterol-lowering and antioxidant lowering on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493.
15. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KJ, on behalf of the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol level: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-2540.
16. Blankenhorn, DH, Azen SD, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LMV, Mahrer PR, Masteller MJ, Vailas LI, Alaopovic P, Hirsch LJ, and the MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-976.
17. Furberg CD, Adams HP Jr, Applegate WB, Byingron RP, Espeland MA, Hartweell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B, for the Asyptomatic Carotid Artery Progression Study (ACAPS). Effects of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994;90:1679-1687.
18. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
19. Shepard J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
20. Sachs FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009. Aggressive Lipid Lowering in Post-Coronary Angioplasty Patients with Elevated Cholesterol (the Lovastatin Restenosis Trial)